172
Participants
Start Date
July 29, 2024
Primary Completion Date
August 1, 2027
Study Completion Date
August 1, 2028
VACl
Azacitidine:75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100 mg d1, 200mg d2, 400mg d3-28) Cladribine: 5mg/m2 IV over approximately 1 to 2 hours, daily on days 1-3.
VACh
Azacitidine: 75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100mg d1, 200mg d2, 400mg d3-28) Chidamide: 10mg orally daily for 12 days
VACl Alternating With VACh
"VACl:~Azacitidine:75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100 mg d1, 200mg d2, 400mg d3-28) Cladribine: 5mg/m2 IV over approximately 1 to 2 hours, daily on days 1-3.~VACh:~Azacitidine: 75mg/m2 Subcutaneous daily for 7 days Venetoclax: orally once daily (100mg d1, 200mg d2, 400mg d3-28) Chidamide: 10mg orally daily for 12 days"
VA
Azacitidine: 75mg/m2 Subcutaneous (SC) daily for 7 days Venetoclax: orally once daily (100mg d1, 200mg d2, 400mg d3-28).
RECRUITING
The First Affliated Hospital of Soochow University, Suzhou
Jining Medical University
OTHER
Qilu Hospital of Shandong University
OTHER
The Affiliated Hospital of Qingdao University
OTHER
The First Affiliated Hospital of Anhui Medical University
OTHER
Tongji Hospital
OTHER
The First Affiliated Hospital of Bengbu Medical University
OTHER
The First Affiliated Hospital of Soochow University
OTHER